Top Markets
#1 CyberDEX CyberDEX +372.54%
#2 OVERTAKE OVERTAKE +56.57%
#3 ALEO ALEO +43.43%
#4 Nillion Nillion +34.21%
#5 Clearpool Clearpool +27.85%
#6 Playnance Playnance +23.56%
#7 deBridge deBridge +23.20%
#8 龙虾 (Lobster) 龙虾 (Lobster) +19.17%
#9 AUKI AUKI +18.69%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +16.88%
Coin of the day
CyberDEX CyberDEX
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCI
Peringkat dalam Saham #37499
Intellipharmaceutics International Inc., founded in Toronto, Canada, in 1998,... Intellipharmaceutics International Inc., founded in Toronto, Canada, in 1998, is a pharmaceutical company that focuses on the research, development, and manufacturing of innovative and generic controlled-release and targeted-release oral solid dosage medications, primarily for the United States market. The company leverages its patented Hypermatrix technology to create advanced drug delivery systems, an array of product candidates, and a robust pipeline across diverse therapeutic areas, including neurological, cardiovascular, gastrointestinal, diabetes, and pain management conditions. Its current product portfolio includes extended-release formulations like Focalin XR for hyperactivity disorder, Keppra XR for partial onset seizures, Effexor XR to treat depression, and Protonix for gastroesophageal reflux disease. Other offerings feature Glucophage XR for type 2 diabetes, Seroquel XR for schizophrenia and mood disorders, Lamictal XR for epilepsy, Pristiq for depression, Coreg CR for heart failure and hypertension, and Ranexa for chronic angina. Furthermore, Intellipharmaceutics is actively developing additional controlled-release drugs such as OxyContin for pain relief and Regabatin XR for neuropathic pain management. The company operates under a license and commercialization agreement with Par Pharmaceutical Inc.
Harga Saham
$0.05897422
Terakhir disinkronkan: 2024-04-02
Kapitalisasi Pasar
$1.64M
Perubahan (1 hari)
0.07%
Perubahan (1 tahun)
-60.68%
Negara
CA
Perdagangan Intellipharmaceutics International Inc. (IPCI)

Kategori

Healthcare
Pendapatan untuk Intellipharmaceutics International Inc. (IPCI)
Pendapatan pada Aug 2023 TTM: $904.95K
Menurut laporan keuangan terbaru dari Intellipharmaceutics International Inc., pendapatan saat ini (TTM) adalah $904.95K. Pada tahun 2021, perusahaan menghasilkan pendapatan sebesar $65.73K penurunan dibandingkan dengan pendapatan pada tahun 2020 yang sebesar $1.40M. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Intellipharmaceutics International Inc. dari 1999 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Mengubah
2026 (TTM) $904.95K 1,276.80%
2022 $65.73K 0.00%
2021 $65.73K -95.31%
2020 $1.40M 0.00%
2019 $1.40M -18.17%
2018 $1.71M -68.88%
2017 $5.50M 144.97%
2016 $2.25M -45.11%
2015 $4.09M -53.32%
2014 $8.77M 474.13%
2013 $1.53M 1,326.33%
2012 $107.09K -78.66%
2011 $501.81K -65.61%
2010 $1.46M 0.00%
2008 0.00 0.00%
2007 0.00 0.00%
2006 0.00 0.00%
2005 0.00 0.00%
2004 0.00 0.00%
2003 0.00 0.00%
2002 0.00 -100.00%
2001 $1.00K 0.02%
2000 $999.82 -99.00%
1999 $100.06K 0.00%
Pendapatan untuk perusahaan serupa atau pesaing
Perusahaan Pendapatan Perbedaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 1,394,933.52%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 246,102.54%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 1,739,708.47%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 665,275.32%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH